NewsBite

Proteomics International Laboratories

Advertisement
Proteomics International Laboratories ls launching its PromarkerEso oesophageal cancer test globally, backed by a top-tier clinical board of global gastrointestinal and cancer diagnostic experts.

Medical big guns help Proteomics rev up Aussie cancer test rollout

Proteomics International Laboratories will launch its PromarkerEso oesophageal cancer test globally, backed by a top-tier board of gut and cancer experts.

  • James Pearson

Latest

A Proteomics International Laboratories subsidiary has received an Australian patent for its finger-prick blood test that tracks muscle stress in athletes.

Proteomics nears launch of groundbreaking muscle stress test

Proteomics International Laboratories’ OxiDx has secured an Australian patent for a finger-prick test to measure muscle stress tied to 70 diseases and sports injuries.

  • James Pearson
Assay plates on an automated platform using PromarkerD to test for the early signs of chronic kidney disease in type 2 diabetes patients.

Proteomics launches predictive kidney disease test in Australia

Proteomics International Laboratories has launched its novel PromarkerD test for diabetic kidney disease in WA and the NT before expanding Australia-wide.

  • James Pearson
Results from a trial of Proteomics International Laboratories’ PromarkerD blood test for the detection of chronic kidney disease have been published in a special edition of the peer-reviewed Diagnostics medical journal.

Perth trial proves worth of Proteomics diabetes-related blood test

Proteomics International Laboratories’ PromarkerD blood test has proven to be a step up in predicting chronic kidney disease in a WA-based study of diabetes patients.

  • James Pearson
Proteomics International Laboratories has opened a new laboratory in the United States, certified by the State of California, to roll out its novel PromarkerD kidney disease test.

New Proteomics US testing lab opens door to vast diagnostic market

Proteomics International Laboratories can roll out its novel diabetes-related blood test in the US, having received certification for its Californian reference lab.

  • James Pearson
OxiDx, a majority-owned subsidiary of biotech company Proteomics International, has revealed a simple fingerprick test to detect and monitor muscle damage in elite athletes.

Proteomics world-first blood test tracks muscle recovery in athletes

A Proteomics International subsidiary has unveiled a novel fingerprick test to track muscle damage in elite runners, transforming recovery and performance management in athletes.

  • James Pearson
Advertisement
Proteomics International’s game-changing PromarkerEndo diagnostic blood test for endometriosis has passed its latest clinical trials with flying colours.

Proteomics nails near perfect results for endometriosis blood test

Proteomics International soared 24pc to 75c on news its PromarkerEndo test could successfully diagnose all stages of endometriosis, which affects 10pc of women.

  • James Pearson
Proteomics has revealed high levels of accuracy for its simple “PromarkerEso” blood test that is used to detect esophageal cancer.

Proteomics lands blow on deadly esophageal cancer

Proteomics International Laboratories has boosted its fight against a deadly form of cancer after its blood test showed a detection accuracy of 94 per cent.

  • Bart Bogacz
Dr James Williams, a biotech industry veteran, has been appointed to the board of Proteomics International Laboratories as a non-executive director.

Proteomics adds biotech stalwart to boost diagnostics growth

Proteomics International Laboratories has hired industry veteran Dr James Williams to help guide it towards commercialising its predictive diagnostics tools.

  • James Pearson
Proteomics International Laboratories’ PromarkerD test has shown to be highly accurate in predicting future kidney disease in type 1 diabetes patients.

Proteomics testing pinpoints future kidney disease risks

Proteomics International Laboratories’ “PromarkerD” testing has shown a high accuracy in predicting future kidney disease in type 1 diabetes patients.

  • James Pearson

Original URL: https://www.theage.com.au/topic/piq-18o